ABSTRACT
The clinical adoption of Large Language Models (LLMs) in biomedical research has been limited by concerns regarding the quality, accuracy, and reliability of their outputs, particularly in precision oncology, where clinical decision-making demands high precision. Current models, often based on fine-tuned foundational LLMs, are prone to issues such as hallucinations, incoherent reasoning, and loss of context. In this work, we present GeneSilico Copilot, an advanced agent-based architecture that transforms LLMs from simple response synthesizers to clinical reasoning systems. Our approach is centred around a bespoke ReAct agent that orchestrates a suite of specialized tools for asynchronous information retrieval and synthesis. These tools access curated document vector stores containing clinical treatment guidelines, genomic insights, drug information, clinical trials, and breast cancer-specific literature. To leverage large context windows of current LLMs, we implement a hybrid search strategy that prioritizes key information and dynamically integrates summarized content, reducing context fragmentation. Incorporating additional metadata further allows for precise, transparent and evidence-backed reasoning at each step of the thought process. The system ensures that at every stage, the agent can synthesize meaningful, context-aware observations that contribute to a coherent and comprehensive final response that aligns with clinical standards. Evaluations on real-world breast cancer cases show that GeneSilico Copilot significantly improves response accuracy and personalization. This system represents a critical advancement toward making LLMs clinically deployable in precision oncology and has potential applications in broader medical domains requiring complex, data-driven decision-making.
Competing Interest Statement
A provisional patent has been filed on 10/02/2024 (DW No.: 107881-00009, Serial No.: 63/702,408) describing the agentic framework. All the authors, except for SB are GeneSilico, Inc. employees/partners.
Funding Statement
The entire study is funded by GeneSilico, Inc.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
The study used openly available human data sources such as Pubmed, PharmGKB, Clinical Trial databases, DrugBank Open Data, and NCCN/ASCO/ESMO.
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
Footnotes
↵§ co-first authors
Contains updated methodology section with more details. Supplementary section is also updated.
Data Availability
This is already mentioned in the Data Availability section of the manuscript.